methyl (5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetate
• 英文别名: Methyl (5-{4-[(3,4-dichloro-benzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetate；methyl 2-[5-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]imidazo[1,2-c]pyrimidin-8-yl]acetate
• 化学式: C₂₃H₁₈Cl₂N₄O₃
• 分子量: 469.327
• InChiKey: FJRYRWBVOHCAJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl (5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetate 在 甲醇 、 sodium hydroxide 、 水 、 盐酸 作用下， 反应 1.0h， 以71%的产率得到(5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES
  [FR] DERIVES D'ACIDE IMIDAZO[1,2-C]PYRIMIDINYLACETIQUE

  摘要：

  公开号：

  WO2005073234A3
• 作为产物：
  描述：

  methyl [5-(4-aminobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate 、 3,4-二氯苯甲酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 methyl (5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetate
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES
  [FR] DERIVES D'ACIDE IMIDAZO[1,2-C]PYRIMIDINYLACETIQUE

  摘要：

  公开号：

  WO2005073234A3

文献信息

• Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives
  申请人：Ly Tai-wei

  公开号：US20090012102A1

  公开（公告）日：2009-01-08

  The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

  本发明涉及一种咪唑[1,2-c]嘧啶基乙酸衍生物及其盐，其可用作制药制剂的活性成分。本发明的咪唑[1,2-c]嘧啶基乙酸衍生物具有优异的CRTH2（G蛋白偶联趋化因子受体，表达在Th2细胞上）拮抗活性，可用于预防和治疗与CRTH2活性相关的疾病，特别是用于过敏性疾病的治疗，如哮喘、过敏性鼻炎、特应性皮炎和过敏性结膜炎；嗜酸性粒细胞相关疾病，如Churg-Strauss综合征和鼻窦炎；嗜碱性粒细胞相关疾病，如嗜碱性白血病、慢性荨麻疹和人类及其他哺乳动物的嗜碱性白细胞增多症；以及以T淋巴细胞和大量白细胞浸润为特征的炎症性疾病，如牛皮癣、湿疹、炎症性肠病、溃疡性结肠炎、克罗恩病、慢性阻塞性肺疾病和关节炎。
• Imidazo[1,2-C]pyrimidinylacetic acid derivatives
  申请人：Actimis Pharmaceuticals, Inc.

  公开号：US07750014B2

  公开（公告）日：2010-07-06

  The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

  本发明涉及一种咪唑[1,2-c]嘧啶基乙酸衍生物及其盐，该衍生物可用作制药制剂的活性成分。本发明的咪唑[1,2-c]嘧啶基乙酸衍生物具有优异的CRTH2（表达于Th2细胞上的G蛋白偶联趋化因子受体）拮抗活性，可用于预防和治疗与CRTH2活性相关的疾病，特别是用于治疗过敏性疾病，如哮喘、过敏性鼻炎、特应性皮炎和过敏性结膜炎；嗜酸性粒细胞相关疾病，如Churg-Strauss综合征和鼻窦炎；嗜碱性粒细胞相关疾病，如嗜碱性白血病、慢性荨麻疹和人类及其他哺乳动物的嗜碱性白细胞增多症；以及以T淋巴细胞和大量白细胞浸润为特征的炎症性疾病，如牛皮癣、湿疹、炎症性肠病、溃疡性结肠炎、克罗恩病、慢性阻塞性肺疾病和关节炎。
• IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES
  申请人：Actimis Pharmaceuticals, Inc.,

  公开号：EP1718649B1

  公开（公告）日：2009-06-10
• US7750014B2
  申请人：——

  公开号：US7750014B2

  公开（公告）日：2010-07-06
• [EN] IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE IMIDAZO[1,2-C]PYRIMIDINYLACETIQUE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005073234A3

  公开（公告）日：2005-10-06